ZNDTSM for Huntington's Disease

Grant number: 1113686 | Funding period: 2016 - 2016

Completed

Abstract

Huntington’s disease is a devastating neurological disorder, with no drugs currently available to cure or treat the underlying cause. Our recent laboratory work on a drug called PBT2 was the foundation of a encouraging clinical trail for this disease. Here, we propose to investigate a drug called Zn(DTSM) for this disease, which has similar properties to PBT2, but we expect will have a greater effect.

Related publications (2)

Zinc drives vasorelaxation by acting in sensory nerves, endothelium and smooth muscle

AH Betrie, JA Brock, OF Harraz, AI Bush, GW He, MT Nelson, JA Angus, CE Wright, S Ayton

2021-12-01

Zinc, an abundant transition metal, serves as a signalling molecule in several biological systems. Zinc transporters are genetical..

Brain Zinc Deficiency Exacerbates Cognitive Decline in the R6/1 Model of Huntington's Disease.

Scott Ayton, Peng Lei, Ambili T Appukuttan, Thibault Renoir, Simote Foliaki, Feng Chen, Paul A Adlard, Anthony J Hannan, Ashley I Bush

2020-01-01

There is currently no disease-modifying treatment for Huntington's disease (HD), which is characterized by chorea motor impairment..

University of Melbourne Researchers

Ashley Bush

Kevin Barnham

Scott Ayton